Indolent Medullary Thyroid Cancer with a RET Proto-Oncogene Cys618Phe Mutation Presenting As Sporadic Unilateral Pheochromocytoma in a 55-Year-Old Korean Woman
Restricted accessLetterFirst published online March, 2011
Indolent Medullary Thyroid Cancer with a RET Proto-Oncogene Cys618Phe Mutation Presenting As Sporadic Unilateral Pheochromocytoma in a 55-Year-Old Korean Woman
BrandiML, GagelRF, AngeliA, BilezikianJP, Beck-PeccozP, BordiC, Conte-DevolxB, FalchettiA, GheriRG, LibroiaA, LipsCJ, LombardiG, MannelliM, PaciniF, PonderBA, RaueF, SkogseidB, TamburranoG, ThakkerRV, ThompsonNW, TomassettiP, TonelliF, WellsSAJr., MarxSJ. 2001. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab, 86:5658–5671.
2.
PonderBA, PonderMA, CoffeyR, PembreyME, GagelRF, Telenius-BergM, SempleP, EastonDF. 1998. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet, 1:397–401.
3.
American Thyroid Association Guidelines Task Force. KloosRT, EngC, EvansDB, FrancisGL, GagelRF, GharibH, MoleyJF, PaciniF, RingelMD, SchlumbergerM, WellsSAJr.2009. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid, 19:565–612.
4.
PacakK, EisenhoferG, AhlmanH, BornsteinSR, Gimineez–RoquelploA-P, GrossmanAB, KimuraN, MannelliM, McNicolAM, TischlerAS. 2007. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab, 3:92–102.
